BIOG B Share Price Performance
SEK 115.30
17.10 (17.41%)
24.4% undervalued intrinsic discount
SEK 152.50
Fair Value
Price SEK 115.30
AnalystConsensusTarget SEK 152.50
Fair ValueSEK 152.50
Share Pricen/a
Narrative Update • Jul 21
BioGaia AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
BIOG B Community Narratives
AN
Fair Value
·Fair Value SEK 152.5 24.4% undervalued intrinsic discount
Expanding North American Demand Will Unlock New Health Trends
0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
Expanding North American Demand Will Unlock New Health Trends
BioGaia is pushing its probiotics beyond its traditional strongholds by expanding into big-name North American stores and selling more directly to consumers, riding a growing shift toward everyday “preventative” health products. The upside is bigger reach and new product lines, but heavy spending, weaker cash generation, and reliance on children’s products could make the path bumpier than it looks.Read more
AN
SEK 152.5
24.4% undervalued intrinsic discount
Fair Value
Revenue
11.58% p.a.
Profit Margin
27.11%
Future PE
30.25x
Price in 2029
SEK 177.99
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating
Fair Value: SEK 152.5 24.4% undervalued intrinsic discount
14 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioGaia AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Feb 12, 2027
- 3.43
- 73.01%
- 21.97%
- 0%
About BIOG B
- Founded
- 1990
- Employees
- 251
- CEO
- WebsiteView website
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
